Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Inclusion Criteria: * Age between 18 and 80 years * Able to provide informed consent * Underlying diagnosis of SJS, TENS, or MMP * Implantation of a Boston KPro type I * Able to administer eye medications or have a care giver able and willing to do same * Negative tuberculosis screening Exclusion Criteria: * Active or recurrent ocular or systemic infection * Chest radiography, QuantiFERON-TB Gold or purified protein derivative (PPD) evidence of active or latent tuberculosis infection * Indeterminate initial and repeat QuantiFERON-TB Gold results * History of Bacille Calmette-Guerin (BCG) vaccination within twelve months of screening * History of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening * Chest radiograph within three months prior to the first administration of the study drug that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis. * History of a nontuberculous mycobacterial infection or opportunistic infection (e.g. cytomegalovirus, pneumocystosis, aspergillosis) within six months prior to screening * history of hepatitis B virus * Methicillin resistant Staphylococcus aureus (MRSA) or vancomycin resistant enterococcus (VRE) infection * Malignancy diagnosed in the last five years * Demyelinating disease * History or current diagnosis of diabetes mellitus (controlled and uncontrolled) * Heart failure (New York Heart Association class III or IV) * Pregnancy or breast-feeding * Scheduled to receive a live vaccine at any time point during study participation * Allergy to infliximab or any of the compounds in its topical formulation or any chemically-related medication * Prior or current use of systemic anti-tumor necrosis alpha-α medications or currently receiving treatments of Kineret (Anakinra) * KPro designs with less than 16 holes in the back plate (to avoid the confounder of corneal nutrition) * Inability to comply with the instillation of additional drops * Unable to attend postoperative visits or administer medications, or no care giver available and willing to assist with same